CAS RN: 100986-89-8 | Product Number: L0238
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
|Appearance||White to Light yellow powder to crystal|
|Purity(HPLC)||min. 98.0 area%|
|Purity(Neutralization titration)||min. 98.0 %|
|Specific rotation [a]20/D||-62.0 to -64.0 deg(C=1、DMSO)|
|Specific Rotation||-64° (C=1,DMSO)|
|Hazard Statements||H315 : Causes skin irritation.
H319 : Causes serious eye irritation.
|Precautionary Statements||P264 : Wash skin thoroughly after handling.
P280 : Wear protective gloves/ eye protection/ face protection.
P302 + P352 : IF ON SKIN: Wash with plenty of water.
P337 + P313 : If eye irritation persists: Get medical advice/ attention.
P362 + P364 : Take off contaminated clothing and wash it before reuse.
P332 + P313 : If skin irritation occurs: Get medical advice/ attention.
- Synthesis and antibacterial activities of optically active ofloxacin
- Synthesis and antibacterial activities of optically active ofloxacin and its fluoromethyl derivative
- Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl- 10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin)
- A validated stability-indicating RP-HPLC method for levofloxacin in the presence of degradation products, its process related impurities and identification of oxidative degradant
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
C of A & Other Certificates
The requested analytical chart is not available. Sorry for the inconvenience.